Literature DB >> 18263627

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Clifford R Jack1, Val J Lowe, Matthew L Senjem, Stephen D Weigand, Bradley J Kemp, Maria M Shiung, David S Knopman, Bradley F Boeve, William E Klunk, Chester A Mathis, Ronald C Petersen.   

Abstract

To date, most diagnostic imaging comparisons between amyloid labelling ligands and other imaging modalities have been between the use of amyloid labelling ligand (11)C Pittsburgh Compound B (PiB) and FDG-PET. Our objectives were to compare cognitive performance and diagnostic group-wise discrimination between cognitively normal, amnestic mild cognitive impairment (MCI) and Alzheimer's disease subjects with MRI-based measures of hippocampal volume and PiB retention, and secondly to evaluate the topographic distribution of PiB retention and grey matter loss using 3D voxel-wise methods. Twenty cognitively normal, 17 amnestic MCI and 8 probable Alzheimer's disease subjects were imaged with both MRI and PiB. PiB retention was quantified as the ratio of uptake in cortical to cerebellar regions of interest (ROIs) 40-60 min post-injection. A global cortical PiB retention summary measure was derived from six cortical ROIs. Statistical parametric mapping (SPM) and voxel-based morphometry (VBM) were used to evaluate PiB retention and grey matter loss on a 3D voxel-wise basis. Alzheimer's disease subjects had high global cortical PiB retention and low hippocampal volume; most cognitively normal subjects had low PiB retention and high hippocampal volume; and on average amnestic MCI subjects were intermediate on both PiB and hippocampal volume. A target-to-cerebellar ratio of 1.5 was used to designate subjects with high or low PiB cortical retention. All Alzheimer's disease subjects fell above this ratio, as did 6 out of 20 cognitively normal subjects and 9 out of 17 MCI subjects, indicating bi-modal PiB retention in the latter two groups. Interestingly, we found no consistent differences in learning and memory performance between high versus low PiB cognitively normal or amnestic MCI subjects. The SPM/VBM voxel-wise comparisons of Alzheimer's disease versus cognitively normal subjects provided complementary information in that clear and meaningful similarities and differences in topographical distribution of amyloid deposition and grey matter loss were shown. The frontal lobes had high PiB retention with little grey matter loss, anteromedial temporal areas had low PiB retention with significant grey matter loss, whereas lateral temporoparietal association cortex displayed both significant PiB retention and grey matter loss. A voxel-wise SPM conjunction analysis revealed that subjects with high PiB retention shared a common PiB retention topographical pattern regardless of clinical category, and this matched that of amyloid plaque distribution from autopsy studies of Alzheimer's disease. Both global cortical PiB retention and hippocampal volumes demonstrated significant correlation in the expected direction with cognitive testing performance; however, correlations were stronger with MRI than PiB. Pair-wise inter-group diagnostic separation was significant for all group-wise pairs for both PiB and hippocampal volume with the exception of the comparison of cognitively normal versus amnestic MCI, which was not significant for PiB. PiB and MRI provided complementary information such that clinical diagnostic classification using both methods was superior to using either in isolation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18263627      PMCID: PMC2730157          DOI: 10.1093/brain/awm336

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  81 in total

Review 1.  Voxel-based morphometry--the methods.

Authors:  J Ashburner; K J Friston
Journal:  Neuroimage       Date:  2000-06       Impact factor: 6.556

2.  Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease.

Authors:  S A Rombouts; F Barkhof; M P Witter; P Scheltens
Journal:  Neurosci Lett       Date:  2000-05-19       Impact factor: 3.046

3.  "Preclinical" AD revisited: neuropathology of cognitively normal older adults.

Authors:  F A Schmitt; D G Davis; D R Wekstein; C D Smith; J W Ashford; W R Markesbery
Journal:  Neurology       Date:  2000-08-08       Impact factor: 9.910

4.  Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.

Authors:  N M Kemppainen; S Aalto; I A Wilson; K Någren; S Helin; A Brück; V Oikonen; M Kailajärvi; M Scheinin; M Viitanen; R Parkkola; J O Rinne
Journal:  Neurology       Date:  2006-09-13       Impact factor: 9.910

5.  [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.

Authors:  M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

6.  PET of brain amyloid and tau in mild cognitive impairment.

Authors:  Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

7.  Automated template-based PET region of interest analyses in the aging brain.

Authors:  Felice T Sun; Roberta A Schriber; Joel M Greenia; Jiawei He; Amy Gitcho; William J Jagust
Journal:  Neuroimage       Date:  2006-11-16       Impact factor: 6.556

8.  Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy.

Authors:  R H Christie; B J Bacskai; W R Zipfel; R M Williams; S T Kajdasz; W W Webb; B T Hyman
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

9.  In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease.

Authors:  J C Baron; G Chételat; B Desgranges; G Perchey; B Landeau; V de la Sayette; F Eustache
Journal:  Neuroimage       Date:  2001-08       Impact factor: 6.556

10.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Authors:  Henry Engler; Anton Forsberg; Ove Almkvist; Gunnar Blomquist; Emma Larsson; Irina Savitcheva; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Brain       Date:  2006-07-19       Impact factor: 13.501

View more
  455 in total

1.  3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.

Authors:  Liana G Apostolova; Kristy S Hwang; John P Andrawis; Amity E Green; Sona Babakchanian; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Ronald C Petersen; Paul S Aisen; William J Jagust; Robert A Koeppe; Chester A Mathis; Michael W Weiner; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

2.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

Authors:  A Caroli; G B Frisoni
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

Review 3.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

4.  Characterizing Alzheimer's disease using a hypometabolic convergence index.

Authors:  Kewei Chen; Napatkamon Ayutyanont; Jessica B S Langbaum; Adam S Fleisher; Cole Reschke; Wendy Lee; Xiaofen Liu; Dan Bandy; Gene E Alexander; Paul M Thompson; Leslie Shaw; John Q Trojanowski; Clifford R Jack; Susan M Landau; Norman L Foster; Danielle J Harvey; Michael W Weiner; Robert A Koeppe; William J Jagust; Eric M Reiman
Journal:  Neuroimage       Date:  2011-01-27       Impact factor: 6.556

5.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

6.  Factors associated with resistance to dementia despite high Alzheimer disease pathology.

Authors:  D Erten-Lyons; R L Woltjer; H Dodge; R Nixon; R Vorobik; J F Calvert; M Leahy; T Montine; J Kaye
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

7.  Association of gray matter atrophy with age, β-amyloid, and cognition in aging.

Authors:  Hwamee Oh; Cindee Madison; Sylvia Villeneuve; Candace Markley; William J Jagust
Journal:  Cereb Cortex       Date:  2013-02-06       Impact factor: 5.357

8.  Aβ-related hyperactivation in frontoparietal control regions in cognitively normal elderly.

Authors:  Hwamee Oh; Jason Steffener; Qolamreza R Razlighi; Christian Habeck; Dan Liu; Yunglin Gazes; Sarah Janicki; Yaakov Stern
Journal:  Neurobiol Aging       Date:  2015-08-24       Impact factor: 4.673

9.  Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis.

Authors:  Liping Fu; Linwen Liu; Jinming Zhang; Baixuan Xu; Yong Fan; Jiahe Tian
Journal:  Eur Radiol       Date:  2014-08-06       Impact factor: 5.315

10.  Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; David S Knopman; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell; Dennis W Dickson
Journal:  Alzheimers Dement       Date:  2019-05-02       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.